施贵宝Izalontamab Brengitecan在TNBC和ESCC中展现显著的OS与PFS改善

美股速递
Jun 02

施贵宝公司宣布,其候选药物Izalontamab Brengitecan在三阴性乳腺癌和食管鳞状细胞癌的临床试验中,取得了总生存期与无进展生存期的显著改善。这一积极数据为相关癌症患者带来了新的治疗希望。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10